HAUSFELD-&-CO-LLP
Fra 12. til 16. juli 2021 vil Competition Appeal Tribunal (CAT) tage stilling til, hvorvidt det skal godkende en begæring om kollektivt søgsmål/gruppesøgsmål (FX Claim UK ) indbragt af Phillip Evans, repræsentant for gruppen og tidligere formand for undersøgelseskomitéen ved den britiske Competition and Markets Authority. Søgsmålet er rettet mod enheder, der indgår i følgende bankkoncerner: Barclays, Citibank, The Royal Bank of Scotland/NatWest, JPMorgan, UBS og MUFG Bank.
Hver af bankerne har indrømmet overtrædelser af EU's konkurrencelovgivning i forbindelse med spothandel med valuta. Phillip Evans’ foreslåede krav søger kompensation fra bankerne på vegne af foreslåede grupper af personer, som hævdes at have lidt tab som følge af bankernes deltagelse i de pågældende overtrædelser.
CAT har udstedt en bekendtgørelse vedrørende dette retsmøde, som kan findes her .
Phillip Evans har engageret Hausfeld & Co LLP, et førende advokatfirma inden for tvister og konflikter, til at føre sagen. Hausfeld & Co LLP’s amerikanske søsterselskab, Hausfeld LLP, er et af de førende advokatfirmaerne i et lignende kollektivt søgsmål i USA, der inddrev mere end 2,3 mia. USD til personer, som var blevet berørt af overtrædelser mht. valutahandel i USA.
Phillip Evans' begæring anmoder CAT om at godkende kravet som kvalificeret til at fortsætte som kollektivt søgsmål på vegne af berettigede enheder og enkeltpersoner samt at godkende, at Phillip Evans agerer som repræsentant for gruppen.
CAT behandler Phillip Evans' begæring samtidigt med en anden begæring om kollektivt søgsmål relateret til valutahandelskarteller, der er fremsat af Michael O’Higgins FX Class Representative Limited. Det betyder, at CAT skal afgøre, hvilken af repræsentanterne der er bedst egnet til at handle som repræsentant for gruppen. Dette er første gang, at CAT er blevet bedt om at afklare en tvist af denne type i relation til kollektive søgsmål.
Enhver person med interesse i de to begæringer (herunder foreslåede medlemmer af gruppen) kan gøre indsigelse mod en af eller begge begæringerne eller bemyndigelsen af en af eller begge foreslåede repræsentanter ved at kontakte CAT og angive deres grunde til at gøre indsigelse senest kl. 16.00 den 4. maj 2021. Disse personer kan også anmode om tilladelse til at fremsætte skriftlige og/eller mundtlige bemærkninger under retsmødet i juli ved at sende en ansøgning herom, understøttet med begrundelser, til domstolen senest kl. 16.00 den 4. maj 2021.
Phillip Evans udtaler: "Det er i gruppens medlemmers interesse, at spørgsmål om certificering og valg af repræsentant afgøres så hurtigt som muligt. Det glæder mig, at domstolen har besluttet at afholde retsmødet om certificeringen i juli 2021."
Med forbehold for eventuelle ændringer som følge af Covid-19-pandemien vil retsmødet finde sted i Competition Appeal Tribunal, Salisbury Square House, 8 Salisbury Square, London EC4Y 8AP. For oplysninger om, hvordan du deltager i domstolens behandling af de to begæringer ved at aflevere skriftlige bemærkninger eller for at ansøge om at blive hørt ved retsmødet i juli, skal du gå ind på www.fxclaimuk.com og læse CATs bekendtgørelse her .
Slut
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20210222005078/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Lone Star Announces Sale of SPX FLOW to ITT Inc.5.12.2025 13:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced the signing by an affiliate of Lone Star Fund XI, LP of a definitive agreement to sell SPX FLOW, Inc. (“SPX FLOW”), a leading provider of highly engineered equipment and process technologies for attractive end markets including industrial, health and nutrition, to ITT Inc. (NYSE: ITT) for $4.775 billion in cash and shares of common stock. Based in Charlotte, N.C., SPX FLOW focuses on process technologies delivering mixing, blending, fluid handling, separation, thermal heat transfer and other solutions integral to industrial, health and nutrition markets. The company has operations in more than 25 countries and sales in more than 140 countries. In partnership with Lone Star, SPX FLOW has focused on improving its sales execution and operating platform, while ensuring high quality and innovative product development. The management team has improved the company’s commercial organization and executed growth initiatives to build its presence in e
AmTrust Financial Services and Blackstone Credit & Insurance Close Strategic Transaction and Launch Newly Formed Multinational MGACompany Named ANV Group Holdings Ltd.5.12.2025 13:00:00 CET | Press release
Strategic Transaction Unlocks Value for AmTrust and Positions ANV Group Holdings for Accelerated GrowthFormer AmTrust President Adam Karkowsky Leading ANV Group Holdings as Chairman and CEO AmTrust Financial Services, Inc. (“AmTrust” or the “Company”), a global specialty property casualty insurer, and Blackstone Credit & Insurance (“BXCI”), today announced the closing of a strategic transaction under which AmTrust and funds managed by BXCI have partnered to spin-off certain of AmTrust’s Managing General Agencies (“MGAs”) and fee-based businesses in the U.S., United Kingdom, and Continental Europe, into ANV Group Holdings Ltd. (“ANV”), a newly formed independent company, following receipt of regulatory approvals. AmTrust and ANV have entered into a ten-year capacity agreement through which AmTrust will remain the underwriter for the existing books of business offered through the MGAs. As previously announced on September 15, 2025, the agreement includes seven AmTrust subsidiaries: ANV S
Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body5.12.2025 07:00:00 CET | Press release
Sculptra®, the first proven regenerative biostimulator, has received European Union (EU) Medical Device Regulation (MDR) certification, expanding its current clinical application for the face to include gluteal area, posterior thighs, décolletage, and upper arms1 Studies investigating the efficacy of Sculptra on areas beyond the face show patients experienced progressive improvements in skin quality (including the improvement in cellulite appearance), firmness, lift, projection, and contour Sculptra’s versatility and new indication allow practitioners to shift patient treatment goals beyond rejuvenation toward enhancement, meeting evolving patient needs The certification validates Sculptra’s safety performance, efficacy, and quality, reinforcing Galderma’s commitment to innovation and meeting evolving patient needs Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its
Northern Escape Heli-Skiing Takes the Title of “World’s Best Heli-Ski-Operator” for the 4th Year Running5.12.2025 02:40:00 CET | Press release
4x World’s Best Heli-Skiing Operation near Terrace, BC Northern Escape Heli-Skiing (NEH) has been named World’s Best Heli-Ski Operator 2025 by the World Ski Awards, marking its fourth straight victory following years 2022, 2023 and 2024. This recognition places NEH amongst an elite group of ski tourism operators consistently voted best in the world by industry leaders and enthusiasts alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204074550/en/ A four-year run built on reliability NEH operates in British Columbia’s Skeena Mountains, where deep northern snow and vast terrain come together with small-group heli-skiing and heli snowboarding. When helicopters can’t safely fly, NEH has cat skiing readily available as a backup — an exceedingly rare offering in this industry. The operation spans over 833,571 wild acres of alpine bowls, glaciers and old-growth tree skiing. The NEH experience Guests choose from three lodge f
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance5.12.2025 01:00:00 CET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollment in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers. IDE034 is a bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and licensed to IDEAYA in July 2024. The IND clearance marks an important milestone for this licensed program, supporting subsequent clinical development of IDE034, while highlighting Biocytogen’s technical capabilities in bispecific ADC discovery and development. Dr. Yue
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum